Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Dillon

Showing results (1-10 of 101) with videos related to

Pageof 11
Sort By:
Blood|July 9, 2016
Just 1 test to diagnose AML?!!Richard Dillon, David Grimwade
Leukemia & Lymphoma|December 10, 2013
Prognostic significance of additional cytogenetic abnormalities and FLT3 mutations in acute promyelocytic leukemiaRichard Dillon, David Grimwade
The Lancet. Haematology|May 15, 2023
Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?Jad Othman, Richard Dillon
British Journal of Hospital Medicine (London, England : 2005)|March 11, 2009
Full blood countRichard Dillon, Claire Harrison
Blood Cancer Discovery|November 2, 2023
Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AMLBrunangelo Falini, Richard Dillon
Frontiers in Oncology|December 2, 2020
UK Experience of an Alternative ATO Dosing Regimen in APLNigel Russell, Richard Dillon
Expert Review of Hematology|April 24, 2024
Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemiaHåkon Reikvam, Richard Dillon
American Journal of Hematology|September 25, 2024
Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug developmentNicholas J Short, Richard Dillon
Clinical Medicine (London, England)|December 2, 2010
Lyme disease in the U.K.: clinical and laboratory features and response to treatmentRichard Dillon, Susan O'Connell, Stephen Wright
Clinical Lymphoma, Myeloma & Leukemia|April 12, 2026
SOHO State of the Art Updates and Next Questions: Is Favorable-risk AML Always Favorable?Aditya Tedjaseputra, Nigel Russell, Richard Dillon
Pageof 11

Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
Blood|July 9, 2016
Just 1 test to diagnose AML?!!Richard Dillon, David Grimwade
Leukemia & Lymphoma|December 10, 2013
Prognostic significance of additional cytogenetic abnormalities and FLT3 mutations in acute promyelocytic leukemiaRichard Dillon, David Grimwade
The Lancet. Haematology|May 15, 2023
Time to add gemtuzumab ozogamicin to intensive chemotherapy for NPM1-mutated acute myeloid leukaemia?Jad Othman, Richard Dillon
British Journal of Hospital Medicine (London, England : 2005)|March 11, 2009
Full blood countRichard Dillon, Claire Harrison
Blood Cancer Discovery|November 2, 2023
Criteria for Diagnosis and Molecular Monitoring of NPM1-Mutated AMLBrunangelo Falini, Richard Dillon
Frontiers in Oncology|December 2, 2020
UK Experience of an Alternative ATO Dosing Regimen in APLNigel Russell, Richard Dillon
Expert Review of Hematology|April 24, 2024
Revisiting the role of measurable residual disease in FLT3 mutated acute myelogenous leukemiaHåkon Reikvam, Richard Dillon
American Journal of Hematology|September 25, 2024
Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug developmentNicholas J Short, Richard Dillon
Clinical Medicine (London, England)|December 2, 2010
Lyme disease in the U.K.: clinical and laboratory features and response to treatmentRichard Dillon, Susan O'Connell, Stephen Wright
Clinical Lymphoma, Myeloma & Leukemia|April 12, 2026
SOHO State of the Art Updates and Next Questions: Is Favorable-risk AML Always Favorable?Aditya Tedjaseputra, Nigel Russell, Richard Dillon
Pageof 11